SERA PROGNOSTICS, INC. (SERA) Operating Margin
- Operating margin · 12 months: Value -53282.86%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -53282.86% | Operating income / revenue. Period ending 2026-06-30. $-37.30M ÷ $70.00K × 100 ≈ -53282.86% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -37.30M USD | Operating Income (Loss) |
| Revenue | 70.00K USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 13.02M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-37.30M | $70.00K | (m) | $13.02M | (m) | -53282.86% |
| 2026-03-31 | $-36.61M | $57.00K | (m) | $12.87M | (m) | -64235.09% |
| 2025-12-31 | $-36.50M | $81.00K | (m) | $13.17M | (m) | -45066.67% |
| 2025-09-30 | $-36.97M | $95.00K | (m) | $13.09M | (m) | -38918.95% |
| 2025-06-30 | $-36.85M | $108.00K | (m) | $13.31M | (m) | -34125.00% |
| 2025-03-31 | $-36.79M | $115.00K | (m) | $14.38M | (m) | -31989.57% |
| 2024-12-31 | $-36.63M | $77.00K | (m) | $14.73M | (m) | -47577.92% |
| 2024-09-30 | $-36.06M | $94.00K | (m) | $15.49M | (m) | -38361.70% |
| 2024-06-30 | $-35.38M | $107.00K | (m) | $15.52M | (m) | -33067.29% |
| 2024-03-31 | $-37.59M | $206.00K | (m) | $14.80M | (m) | -18247.09% |
| 2023-12-31 | $-39.82M | $306.00K | (m) | $15.22M | (m) | -13013.40% |
| 2023-09-30 | $-41.39M | $330.00K | (m) | $14.81M | (m) | -12542.73% |
| 2023-06-30 | $-44.40M | $375.00K | (m) | $15.45M | (m) | -11838.67% |
| 2023-03-31 | $-44.68M | $330.00K | (m) | $15.03M | (m) | -13539.70% |
| 2022-12-31 | $-45.65M | $268.00K | (m) | $14.24M | (m) | -17034.33% |
| 2022-09-30 | $-47.78M | $229.00K | (m) | $13.83M | (m) | -20865.07% |
| 2022-06-30 | $-46.03M | $165.00K | (m) | $12.38M | (m) | -27899.39% |
| 2022-03-31 | $-41.67M | $107.00K | (m) | $11.95M | (m) | -38943.93% |
| 2021-12-31 | $-35.40M | $82.00K | (m) | $11.02M | (m) | -43164.63% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-17.97M | $25.00K | (m) | $7.78M | (m) | -71884.00% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |